title: Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia.
abstract: OBJECTIVE
  Noncognitive behavioral disturbances including agitation and aggression frequently accompany the cognitive symptoms of dementia accounting for much of dementia's morbidity, yet treatment options are currently limited. The authors examine the safety and efficacy of Electroconvulsive Therapy (ECT) for agitation and aggression in dementia patients.
  
  
  METHODS
  Retrospective systematic chart review.
  
  
  METHODS
  McLean Hospital's geriatric neuropsychiatry unit.
  
  
  METHODS
  Sixteen patients with a diagnosis of dementia treated with ECT for agitation/aggression during 2004-2007.
  
  
  METHODS
  Clinical charts were rated on the Pittsburgh Agitation Scale as the primary outcome, the Clinical Global Impression scale and the Global Assessment of Functioning pre- and post-ECT.
  
  
  RESULTS
  16 patients of mean age 66.6 ± 8.3 years were studied. Their average overall and pre-ECT lengths of stay were 59.7 ± 39.7 days and 23 ± 15.7 days, respectively. Patients received a mean of 9 ECT treatments, mostly bilateral. Patients showed significant reductions in their total Pittsburgh Agitation Scale scores from baseline after ECT (from 11.0 ± 5.0 to 3.9 ± 4.3 [F = 30.33, df = 1, 15, p < 0.001]). Clinical Global Impression scale decreased significantly (from 6.0 ± 0.6 pre-ECT to 2.1 ± 1.6 post-ECT [F = 112.97, df = 1, 15, p < 0.001]). Global Assessment of Functioning change was not significant (from 23.0 ± 4.9 to 26.9 ± 6.9 [F = 5.73, df = 1, 13, p = 0.32]). Only one patient, in whom ECT was discontinued following 11 bilateral treatments, showed no improvement. Eight patients showed transient postictal confusion, which typically resolved within 48 hours. Two patients showed more severe postictal confusion that required modification of treatment.
  
  
  CONCLUSIONS
  These results suggest that ECT is an effective and safe treatment for agitation and aggression in dementia. Further prospective studies are warranted.
authors.affiliation: Harvard South Shore Psychiatry Residency Training Program, Boston VA Healthcare System, Department of Psychiatry, Harvard Medical School, Brockton, MA 02301, USA. manjola_ujkaj@hms.harvard.edu
authors.forename: Manjola
authors.initials: M
authors.lastname: Ujkaj
authors.forename: Donald A
authors.initials: DA
authors.lastname: Davidoff
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Seiner
authors.forename: James M
authors.initials: JM
authors.lastname: Ellison
authors.forename: David G
authors.initials: DG
authors.lastname: Harper
authors.forename: Brent P
authors.initials: BP
authors.lastname: Forester
mesh_terms: D000368:Aged; D000374:Aggression / Q000523:psychology*; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000523:psychology / Q000706:statistics & numerical data; D003704:Dementia / Q000150:complications / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D004565:Electroconvulsive Therapy / Q000009:adverse effects / Q000523:psychology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011595:Psychomotor Agitation / Q000150:complications / Q000523:psychology / Q000628:therapy*; D011619:Psychotropic Drugs / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D011619:Psychotropic Drugs